

April 2025 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

NEW DRUG REVIEW

DRUG	INDICATION	FORMULARY COVERAGE	EFFECTIVE DATE
No new drugs reviewed	N/A	N/A	N/A

ADDITIONAL ITEMS REVIEWED

ITEM	DRUGS WITH NEW POLICIES
New Medical Drug Policies (effective 07/01/25)	<ul style="list-style-type: none"> Grafapex Ketamine IV Exclusion Policy